WO2009061853A3 - Mutant interleukin-2 (il-2) polypeptides - Google Patents

Mutant interleukin-2 (il-2) polypeptides Download PDF

Info

Publication number
WO2009061853A3
WO2009061853A3 PCT/US2008/082528 US2008082528W WO2009061853A3 WO 2009061853 A3 WO2009061853 A3 WO 2009061853A3 US 2008082528 W US2008082528 W US 2008082528W WO 2009061853 A3 WO2009061853 A3 WO 2009061853A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
mutant
mutant interleukin
receptor
interleukin
Prior art date
Application number
PCT/US2008/082528
Other languages
French (fr)
Other versions
WO2009061853A2 (en
Inventor
K Dane Wittrup
David V Liu
Original Assignee
Massachusetts Inst Technology
K Dane Wittrup
David V Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, K Dane Wittrup, David V Liu filed Critical Massachusetts Inst Technology
Priority to US12/741,552 priority Critical patent/US8906356B2/en
Publication of WO2009061853A2 publication Critical patent/WO2009061853A2/en
Publication of WO2009061853A3 publication Critical patent/WO2009061853A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to mutant IL-2 polypeptides that act as receptor antagonists. The mutant IL-2 polypeptides bind CD 25 but do not activate the IL-2 receptor. Also provided are methods of using the mutant IL-2 polypeptides, for example, to treat a patient who has cancer or a viral infection. The mutant polypeptides can also be used in various delivery systems.
PCT/US2008/082528 2007-11-05 2008-11-05 Mutant interleukin-2 (il-2) polypeptides WO2009061853A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/741,552 US8906356B2 (en) 2007-11-05 2008-11-05 Mutant interleukin-2 (IL-2) polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98553207P 2007-11-05 2007-11-05
US60/985,532 2007-11-05

Publications (2)

Publication Number Publication Date
WO2009061853A2 WO2009061853A2 (en) 2009-05-14
WO2009061853A3 true WO2009061853A3 (en) 2009-08-13

Family

ID=40626423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/082528 WO2009061853A2 (en) 2007-11-05 2008-11-05 Mutant interleukin-2 (il-2) polypeptides

Country Status (2)

Country Link
US (1) US8906356B2 (en)
WO (1) WO2009061853A2 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008023820A1 (en) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells
MX2011007647A (en) 2009-01-21 2011-09-01 Amgen Inc Compositions and methods of treating inflammatory and autoimmune diseases.
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
GB2488077A (en) 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
CU23734A1 (en) 2009-11-27 2011-11-15 Centro Inmunologia Molecular IMMUNOMODULATOR POLIPEPTIDES DERIVED FROM IL-2 WITH ANTIGONIST ACTIVITY OF THIS CITOCINE USED IN CANCER THERAPY AND CHRONIC INFECTIOUS DISEASES
JP5969458B2 (en) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ Albumin derivatives and variants
DK2638173T3 (en) * 2010-11-08 2019-09-30 Univ Leland Stanford Junior FUSION PROTEINS INCLUDING A MANIPULATED KNOTTIN PEPTIDE AND APPLICATIONS THEREOF
CU23923B1 (en) 2010-11-12 2013-07-31 Ct De Inmunología Molecular POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY
US20140080766A1 (en) * 2011-01-07 2014-03-20 Massachusetts Institute Of Technology Compositions and methods for macromolecular drug delivery
US9266938B2 (en) 2011-02-10 2016-02-23 Roche Glycart Ag Mutant interleukin-2 polypeptides
US20120258073A1 (en) 2011-02-10 2012-10-11 Christian Gerdes Immunotherapy
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
US11441245B2 (en) 2011-09-01 2022-09-13 5.11, Inc. Rip-stop fabric with mechanical stretch fibers
WO2013033719A1 (en) * 2011-09-01 2013-03-07 5.11, Inc. Rip-stop fabric with mechanical stretch fibers
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
SG10201800535XA (en) 2012-08-07 2018-02-27 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
KR20150082422A (en) 2012-11-08 2015-07-15 노보자임스 바이오파마 디케이 에이/에스 Albumin variants
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US20150017120A1 (en) * 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
EP3097420A4 (en) * 2014-01-24 2018-01-17 Ntercept, LLC Methods and compositions for immune dis-inhibition
PL3102595T3 (en) 2014-02-06 2019-04-30 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015233542B2 (en) 2014-03-17 2020-01-16 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Prasidenten A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
EP3134102B1 (en) * 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
MX2017000833A (en) 2014-08-11 2017-11-02 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases.
MX2017003903A (en) 2014-10-03 2017-09-15 Ntercept Llc Compositions and methods for inhibiting the biological activity of soluble biomolecules.
IL283764B2 (en) 2015-04-10 2024-01-01 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
EA201890391A1 (en) 2015-07-29 2018-08-31 НАНОТИКС, ЭлЭлСи MODULAR COMPOSITIONS FOR UTILIZATION OF SOLUBLE BIOMOLECULES AND RELATED METHODS
CA2989966A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CA2997406A1 (en) 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
BR112018076260A2 (en) 2016-06-20 2019-03-26 Kymab Limited antibody or fragment thereof that specifically binds to hpd-11, bispecific antibody or fusion protein, use of an antibody or fragment, method, pharmaceutical composition, modulation method, inhibition method, treatment method, nucleic acid, vector, host and immunocytocin
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018073365A1 (en) 2016-10-19 2018-04-26 F. Hoffmann-La Roche Ag Method for producing an immunoconjugate
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CA3041334A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
WO2018129207A1 (en) 2017-01-04 2018-07-12 Nanotics, Llc Methods for assembling scavenging particles
CN110520436A (en) 2017-03-15 2019-11-29 潘迪恩治疗公司 Target immunological tolerance
RU2761377C2 (en) 2017-04-03 2021-12-07 Ф. Хоффманн-Ля Рош Аг Immunoconjugates of antibody to pd-1 with il-2 or il-15 mutant
WO2018184965A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
CN111615396A (en) * 2017-11-21 2020-09-01 小利兰·斯坦福大学董事会 Partial agonists of interleukin-2
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
MX2020009975A (en) 2018-03-28 2020-10-12 Bristol Myers Squibb Co Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use.
CA3106858A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
EP3875475A4 (en) 2018-12-21 2022-12-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Human interleukin-2 variant or derivative thereof
CN111944036A (en) 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 Mutant protein for proliferating immune cells
KR20220035333A (en) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 MADCAM Targeted Immune Tolerance
AU2020291012A1 (en) 2019-06-12 2021-12-16 AskGene Pharma, Inc. Novel IL-15 prodrugs and methods of use thereof
CN114051500A (en) 2019-07-02 2022-02-15 豪夫迈·罗氏有限公司 Immunoconjugates comprising interleukin-2 mutants and anti-CD 8 antibodies
US20220306714A1 (en) 2019-08-12 2022-09-29 AskGene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
JOP20220036A1 (en) * 2019-08-13 2023-01-30 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
WO2021076805A1 (en) * 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
CA3166509A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
KR20230004682A (en) 2020-04-22 2023-01-06 머크 샤프 앤드 돔 엘엘씨 Human interleukin-2 conjugates biased against the interleukin-2 receptor beta gamma c dimer and conjugated to non-peptide water soluble polymers
US11897930B2 (en) * 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN114369153A (en) * 2020-10-18 2022-04-19 北京志道生物科技有限公司 Interleukin-2 mutant
MX2023005030A (en) 2020-10-29 2023-05-16 Bristol Myers Squibb Co Fusion proteins for the treatment of disease.
CA3201446A1 (en) 2020-11-13 2022-05-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
KR20230117122A (en) 2020-12-04 2023-08-07 에프. 호프만-라 로슈 아게 pH dependent mutant interleukin-2 polypeptide
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
JP2024512709A (en) 2021-03-30 2024-03-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Protease activating polypeptide
CN115867645A (en) 2021-05-18 2023-03-28 赛斯尔擎生物技术（上海）有限公司 Method for modifying cells
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
WO2023004004A1 (en) * 2021-07-23 2023-01-26 Merck Sharp & Dohme Llc Il-2 muteins for treating cancer or infection
WO2023005680A1 (en) 2021-07-30 2023-02-02 西安龙腾景云生物科技有限公司 Human interleukin-2 variant and use thereof
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US20050142106A1 (en) * 2003-07-18 2005-06-30 Wittrup K. D. Mutant interleukin-2 (IL-2) polypeptides
EP1076704B1 (en) * 1998-05-15 2007-01-17 AiCuris GmbH & Co. KG Il-2 selective agonists and antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
CN1235911C (en) 1999-08-09 2006-01-11 利思进药品公司 Multiple cytokine-antibody complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
EP1076704B1 (en) * 1998-05-15 2007-01-17 AiCuris GmbH & Co. KG Il-2 selective agonists and antagonists
US20050142106A1 (en) * 2003-07-18 2005-06-30 Wittrup K. D. Mutant interleukin-2 (IL-2) polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BALAJI M. ET AL.: "Interleukin 2 (IL-2) Variants Engineered for Increased IL-2 Receptor -Subunit Affinity Exhibit Increased Potency Arising from a Cell Surface Ligand Reservoir Effect", MOLECULAR PHARMACOLOTY, vol. 66, 2004, pages 864 - 869 *
HINZ S. ET AL.: "Foxp3 Expression in Pancreatic Carcinoma Cells as a Novel Mechanism of Immune Evasion in Cancer", CANCER RESEARCH, vol. 67, 1 September 2007 (2007-09-01), pages 8343 - 50 *
JOHANNA C. ET AL.: "DAB Interleukin-2 Receptor Binding Domain Mutations", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 21, 1996, pages 12145 - 12149 *

Also Published As

Publication number Publication date
US20110091412A1 (en) 2011-04-21
US8906356B2 (en) 2014-12-09
WO2009061853A2 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
WO2009061853A3 (en) Mutant interleukin-2 (il-2) polypeptides
WO2008145681A3 (en) Ccr2 receptor antagonists and uses thereof
MX2008001652A (en) Polyammonium/polysiloxane copolymers.
WO2008127364A3 (en) Antiviral compounds and use thereof
EP2526934A3 (en) Inhibitors of bruton's tyrosine kinase
WO2008042814A3 (en) Mart-1 t cell receptors
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
WO2008121767A3 (en) Stitched polypeptides
IN2012DN02652A (en)
WO2007022385A3 (en) Use of cxcr4 binding molecules for the treatment of whim syndrome
EP1983002A3 (en) Tyrosine phosphorylation sites and antibodies specific for them
WO2008089397A3 (en) Adrb2 cancer markers
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
WO2008045564A8 (en) Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2007130822A3 (en) Mglur5 modulators iii
TW200606031A (en) Scrapbooking supplies system
TW200726763A (en) Novel compound
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
MX2007008158A (en) Treatment of hcv disorders.
EP1983003A3 (en) Tyrosine phosphorylation sites and antibodies specific for them
WO2012033901A3 (en) Somatostatin receptor-based cancer therapy
MX2009009743A (en) Powders for reconstitution.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08848364

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010533222

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 08848364

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12741552

Country of ref document: US